Dopamine D1 receptor signaling from the Golgi apparatus in murine striatal medium spiny neurons is regulated by monoamine transporter OCT2.

A dopamine transporter deficiency syndrome (DTDS)-linked mutation, R445C, underlies dopamine dysfunction and, more broadly, the clinical phenotypes shared by DTDS and Parkinson’s disease.

Dopamine transporter (DAT) interaction with furopyrimidine called AIM-100 in intact cells leads to dramatic oligomerization, nanoclustering and endocytosis of DAT by a novel mechanism coupled to the transporter molecule conformation.

Subtle differences in handling of intracellular cations can drive macroscopic functional differences in structurally similar monoamine transporters.

Potassium presumably binds to the Na1 site in LeuT, playing a role in inwardly rectifying the transport of substrates.

The molecular mechanisms by which midbrain dopamine neurons acquire the inhibitory neurotransmitter GABA for synaptic release are revealed.

BalaT-dependent β-alanine trafficking pathway in retinal pigment cells is critical for maintaining synaptic transmission of photoreceptor neurons in Drosophila.

The structure of the vesicular monoamine transporter 2 bound to Huntington’s chorea drug tetrabenazine elucidates mechanisms of inhibition and neurotransmitter transport.

The neuronal glutamate transporter EAAC1 limits excitation and lateral inhibition between D1-MSNs, which are important for the execution of slow-switching flexible behaviors.

A combination of electrophysiological, electrochemical, and anatomical experiments sheds new light on how the complex neurotransmitter repertoire of dopaminergic neurons in the brain is regulated by proteins of the neurexin family.